|
MechanismA2aR antagonists |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.JP |
First Approval Date25 Mar 2013 |
|
MechanismHSP90B inhibitors |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
An Observational Study of Diagnostic Criteria, Clinical Features and Management of Opioid-induced Constipation (OIC) in Patients With Cancer Pain
The aim of the project is to investigate OIC in a real world / diverse group of patients with cancer.
The objectives of the project are to determine: a) efficacy of a treatment algorithm to manage OIC; b) efficacy of conventional laxatives to manage OIC; c) efficacy of PAMORAs / other interventions to manage OIC.
An Observational Study of Diagnostic Criteria, Clinical Features and Management of Opioid-induced Constipation (OIC) in Patients With Cancer Pain
The aim of the project is to investigate opioid-induced constipation (OIC) in a real world / diverse group of patients with cancer.
The objectives of the project are to determine: a) prevalence of OIC; b) clinical features / impact of OIC; c) management of OIC.
A Phase I Study to Determine the Pharmacokinetic Profile, Safety and Tolerability of a Single Dose (50IU/kg) of KW-3357 in Subjects With Congenital Antithrombin Deficiency.
The aim of this study is to determine the pharmacokinetics, safety and tolerability of KW-3357 in asymptomatic subjects with congenital antithrombin deficiency.
100 Clinical Results associated with Kyowa Hakko Kirin Uk Ltd.
0 Patents (Medical) associated with Kyowa Hakko Kirin Uk Ltd.
100 Deals associated with Kyowa Hakko Kirin Uk Ltd.
100 Translational Medicine associated with Kyowa Hakko Kirin Uk Ltd.